Auburn University scientists to test anti-tumor properties of new drug

AUBURN – The Auburn University College of Veterinary Medicine and Nuovo Biologics, a biotechnology company, have announced a collaborative research agreement to study a new anti-cancer drug which also has antiviral properties.

Scientists with the Auburn University Research Initiative in Cancer at the College of Veterinary Medicine will be working with Nuovo Biologics to examine the anti-tumor properties of this new drug. These studies will look at the drug from the perspective of its interactions with cells, as well as in clinical trials in dogs with malignant melanoma, a form of skin cancer. Preliminary studies have shown that the drug appears to be safe, with no side effects and active against a wide variety of viruses.

“This agreement exemplifies how Auburn University scientists, working with biotech and pharmaceutical industries, can provide expertise to move exciting new discoveries from the laboratory into the clinic,” said AURIC director Bruce Smith.

The Auburn University Research Initiative in Cancer, or AURIC, embodies the “One Medicine” concept which links human, animal and environmental health and where discoveries in one species advance health in all species. For more information on the initiative, go to

Nuovo Biologics, LLC is a Florida-based animal health company dedicated to the development of drugs, biologics and supplements to enhance animal health and wellness.

(Submitted by Tara Lanier.)

Contact: Tara Lanier, College of Veterinary Medicine, (334) 844-3698, (, or
Mike Clardy, Office of Communications and Marketing, (334) 844-9999 (